Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Debt
Short-term and long-term borrowings combined.
Evommune, Inc.NYSE: EVMN
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 95.3% from a year ago
Total debt stood at $9.11M at the end of Q1 FY2026, down 95.3% from a year earlier and up 342.4% from the prior quarter.
Context
- Total debt amounted to 2.8% of total assets at the end of Q1 FY2026, down 341.6 pp from a year earlier.
- Total debt increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -95.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.06M USD
- Year-over-year change
- -98.9%
- 2-year CAGR
- -88.3%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.06M | -98.9% |
| FY2024 | 2024-12-31 | 193.31M | +28.3% |
| FY2023 | 2023-12-31 | 150.63M | — |
Total Debt vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total debt of $9.11M is the 9th highest of the 10 companies compared; the peer median is $72.9M.
- Its year-over-year change of -95.3% is the lowest of 10, against a peer median of +1.1%.
- Total debt amounts to 2.8% of total assets for EVMN, versus a peer median of 41.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.13B | +19604.9% | +72.6% | 51.8% | |
FTREFortrea Holdings Inc. | Jun 2026 | $1.12B | -10.0% | +160.1% | 41.2% |
| Sep 2026 | $662.71M | +3405.7% | -13.4% | 56.3% | |
| Mar 2026 | $230.87M | +23.7% | +9.3% | 175.7% | |
| Mar 2026 | $72.9M | +22.5% | +18.8% | 56.4% | |
| Mar 2026 | $20.23M | -16.0% | -23.5% | 7.0% | |
| Mar 2026 | $19.67M | -12.5% | -7.6% | 6.7% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.26M | -26.7% | -17.4% | 9.7% |
EVMNEvommune, Inc. | Mar 2026 | $9.11M | -95.3% | — | 2.8% |
CLYMClimb Bio, Inc. | Mar 2026 | $479K | +1.1% | +4.1% | 0.3% |
| Peer median (excluding EVMN) | $72.9M | +1.1% | +4.1% | 41.2% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.